Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07129993) titled 'Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma' on Aug. 12.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daiichi Sankyo
Condition:
Urothelial Cancer
Bladder Cancer
Intervention:
Drug: Dato-DXd
Drug: Carboplatin
Drug: Cisplatin
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: September 26, 2025
Target S...